Company intelligence / Profile preview

OncBioMune Pharmaceuticals, Inc.

Baton Rouge, Louisiana, United Statesoncbiomune.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

ProscaVax has completed Phase 1a trial showing it is non-toxic and can lower PSA levels. The company was moving forward with Phase 2 trials for prostate cancer patients in the "Active Surveillance" category. The Phase 2 trial was scheduled to commence in December 2018 at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard University.[1][6][7]

Therapeutic areas: Oncology
Modalities: VaccinesImmunotherapyTargeted therapiesBiosimilars
Industry: Biotech

Drug pipeline

5 assets

OvcaVax

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Department of Defense Navy Cancer Vaccine Program

Beyond the preview

Go deeper on OncBioMune Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncBioMune Pharmaceuticals, Inc..

Explore the full profile